Lauren Tardo
Neurology · Dallas, TXNPI 1861888075
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (51.3%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. EMD Serono, Inc. accounts for 99.6% of it on its own, with 1 other manufacturer making up the rest.
Across 6 payments — averaging $963.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- EMD Serono, Inc.$6K
- Integra Lifesciences Corporation$23
Across 19 payments — averaging $9862.90 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi$146K
- Novartis$41K
What the payments were for
- Consulting fees$2,70047%
- Food & beverage$1132%
- Education$2,96851%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| EMD Serono, Inc. | 5 | $5,759 |
| Integra Lifesciences Corporation | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Evobrutinib$2,700
How this compares
$5,782 in reported general payments places this provider in the 60th percentile of 1,246 neurology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 24 | $202,624 |
| EnspryngSatralizumab-Mwge | 12 | $194,322 |
| AmpyraDalfampridine | 12 | $48,771 |
| Dimethyl Fumarate | 15 | $22,892 |
| TrexallMethotrexate Sodium | 12 | $2,975 |
| Mycophenolate Mofetil | 15 | $2,301 |
| Baclofen | 56 | $1,835 |
| Gabapentin | 77 | $1,617 |
| Teriflunomide | 11 | $686 |
| Pregabalin | 16 | $596 |
| Amitriptyline Hcl | 24 | $572 |
| Duloxetine Hcl | 29 | $518 |
| Levetiracetam | 15 | $368 |
| Phenobarbital | 17 | $367 |
| Diazepam | 27 | $120 |
Paid to pharmacies, not to this prescriber.
Other neurology in Dallas
- Nirav PavasiaDallas$1.4M
- Benjamin GreenbergDallas$773K
- Waleed El-FekyDallas$587K
- Adnan SubeiDallas$477K
- Steven HerzogDallas$461K
- Priyanka ChaudhryDallas$329K
- Deborah FriedmanDallas$284K
- Mark AlbertsDallas$212K
- Aanchal TanejaDallas$169K
- Salman BhaiDallas$133K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.